News | 17 January 2024
Parexel collaborates with Japanese Foundation for cancer research
Collaboration streamlines patient access to oncology clinical trials
Collaboration streamlines patient access to oncology clinical trials
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
Launch innovative vitamin sublingual sprays
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
Subscribe To Our Newsletter & Stay Updated
